Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that its innovative drugs, Fumetinib Mesylate Tablets (brand name "Aifusha®") and Goleritinib Citrate Tablets (brand name "Airuikai®"), have been included in the National Reimbursement Drug List (NRDL) for 2025. Fumetinib's first-line and second-line treatment indications were successfully renewed through NRDL negotiations, while Goleritinib's second-line treatment indication was newly added to the list via negotiation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments